Peptides for Male Fertility: Research and Protocols

Male infertility affects approximately 7% of men worldwide — though that number likely understates the problem. When couples struggle to conceive, a male factor is involved in roughly half of cases. The causes range from hormonal imbalances to structural abnormalities to lifestyle factors, but one thing has become clear: conventional testosterone replacement therapy often makes the problem worse.

That's where peptides enter the picture.

Unlike exogenous testosterone, which shuts down the body's natural hormone production and halts sperm development, certain peptides work with the reproductive axis rather than against it. They stimulate the body's own systems — the hypothalamus, pituitary, and testes — to produce hormones and support spermatogenesis without triggering suppression.

This guide examines the research on peptides for male fertility, the protocols that clinics use, and what the science actually says about their effectiveness.

Understanding Male Infertility and the HPG Axis

Male infertility isn't rare. Global data shows that infertility affects 8-12% of couples, with males solely responsible for about 20-30% of cases and contributing to roughly 50% overall. Between 1990 and 2019, the global prevalence of male infertility increased by nearly 77%. Sperm quality has been declining worldwide, particularly after 2000.

The causes break down roughly as follows:

Primary testicular defects (65-80%): abnormal sperm parameters without identifiable cause
Idiopathic (10-20%): normal sperm parameters but still infertile
Sperm transport disorders (5%): vasectomy, blockages
Endocrine disorders (2-5%): hormonal dysfunction

Only about 18% of male infertility cases are considered treatable with current interventions.

The Hypothalamic-Pituitary-Gonadal (HPG) Axis

Male reproduction is governed by a three-tier hormonal system:

Hypothalamus → Releases GnRH (gonadotropin-releasing hormone) in pulses

Pituitary → Responds to GnRH by secreting LH (luteinizing hormone) and FSH (follicle-stimulating hormone)

Testes → LH stimulates Leydig cells to produce testosterone; FSH drives Sertoli cells to support spermatogenesis

This system operates on negative feedback. High testosterone levels signal the hypothalamus and pituitary to reduce GnRH, LH, and FSH output. Lower testosterone allows the cycle to ramp back up.

The peptides discussed below interact with this axis at different points — some at the hypothalamus, others at the pituitary, and a few with indirect systemic effects.

The TRT Fertility Problem

Testosterone replacement therapy (TRT) suppresses the HPG axis through negative feedback. When you introduce exogenous testosterone, the body interprets high circulating levels as a signal to stop producing its own. GnRH drops, LH and FSH plummet, and intratesticular testosterone — which needs to be 50-100 times higher than serum levels for spermatogenesis — collapses.

The result: up to 90% of men on TRT experience significant reductions in sperm count, and many become completely infertile while on treatment.

Recovery after stopping TRT is possible but not guaranteed. One study found that patients regained normal hormone levels and sperm concentrations an average of 7.9 months after cessation, but 30% of men were unable to achieve a total motile sperm count above 5 million even after 12 months.

For men who need hormone support but want to preserve fertility, peptides offer an alternative pathway.

Gonadorelin: A GnRH Analog

Gonadorelin is a synthetic version of GnRH. It binds to GnRH receptors in the pituitary gland, triggering the release of LH and FSH — the same hormones the body uses to signal testosterone production and sperm development.

Mechanism

When administered in a pulsatile fashion (mimicking the body's natural rhythm), gonadorelin stimulates Leydig cells to generate testosterone and Sertoli cells to facilitate spermatogenesis. This is fundamentally different from TRT, which bypasses the entire axis.

Clinical Use

Gonadorelin is sometimes used as part of TRT protocols to help reduce or slow testicular shrinkage. It's also explored as a fertility-preserving alternative to HCG (human chorionic gonadotropin), which binds directly to LH receptors in the testes.

The Timing Problem

Here's the catch: gonadorelin only stimulates LH if it's timed correctly. The body's natural GnRH pulses occur roughly every 90-120 minutes. If gonadorelin dosing doesn't approximate this rhythm, it can create a paradoxical suppressive effect — too much constant stimulation desensitizes the receptors, and LH output actually drops.

This is why some clinics use twice-daily injections (typically 100-200 mcg subcutaneously) rather than once-daily dosing. Even then, efficacy varies.

Evidence

Gonadorelin's use in fertility preservation is supported more by clinical practice than robust trials. Reproductive endocrinologists have used GnRH analogs to treat hypogonadotropic hypogonadism — a condition where the hypothalamus or pituitary fails to signal the testes. In those cases, pulsatile GnRH therapy has successfully induced spermatogenesis, though treatment often takes 9-18 months.

For men on TRT who want to maintain fertility, gonadorelin represents a theoretical option, but data comparing it head-to-head with HCG remain limited.

Kisspeptin: The Upstream Regulator

Kisspeptin-10 is a peptide produced in the hypothalamus that sits one step upstream from GnRH. It binds to KISS1 receptors on GnRH neurons, stimulating them to release GnRH in pulses. This makes kisspeptin a master regulator of the entire reproductive axis.

Mechanism

By enhancing GnRH pulses, kisspeptin increases LH and FSH secretion, which in turn supports testosterone production and spermatogenesis. The pathway is indirect but potent.

Research in Men

Human trials have demonstrated that kisspeptin-10 stimulates the HPG axis in healthy men. Intravenous doses as low as 0.3 nmol/kg elevated serum LH, while 1.0 nmol/kg increased FSH. Even short-term administration caused rapid LH increases and subsequent testosterone rises within hours.

A 2017 study found significantly lower serum kisspeptin levels in infertile men compared to fertile men, suggesting that kisspeptin deficiency may play a role in reproductive dysfunction. However, results have been inconsistent — another study reported the opposite pattern, with higher kisspeptin in infertile men.

Despite these contradictions, exogenous kisspeptin administration appears to restore reproductive hormone function. Animal studies in hypothyroid male rats showed that kisspeptin treatment reversed high prolactin levels and improved gonadal function.

Sexual Dimorphism

Kisspeptin's effects differ between men and women. In males, the response tends to be more sustained, whereas in females, the hormone dynamics are more complex due to the menstrual cycle. This sexual dimorphism matters for protocol design.

Clinical Potential

Kisspeptin has been used off-label by men undergoing TRT to boost endogenous testosterone and prevent testicular atrophy. Some clinics position it as an alternative to HCG. The peptide has been safely administered in both healthy and infertile subjects, though long-term safety data remain limited.

Researchers are investigating kisspeptin as both a diagnostic marker (low levels correlating with infertility) and a therapeutic agent. The potential applications include ovarian stimulation protocols in women and fertility restoration in men, though more clinical trials are needed.

HCG: Not a Peptide, But Part of the Conversation

Human chorionic gonadotropin (HCG) is a glycoprotein hormone, not strictly a peptide, but it's discussed alongside peptides because it's commonly used in fertility and TRT protocols.

HCG mimics LH by binding to LH receptors on Leydig cells, stimulating testosterone production and maintaining testicular size. Unlike gonadorelin or kisspeptin, which work upstream, HCG acts directly at the testes.

Protocols

Fertility clinics often start with HCG alone — typically 250-500 IU administered subcutaneously 2-3 times per week — to bring testosterone levels high enough to support spermatogenesis. If sperm production doesn't improve, recombinant FSH may be added. Treatment can take 9-18 months.

HCG is generally considered more effective than gonadorelin for preserving fertility and long-term testicular function, largely because it doesn't depend on pulsatile timing.

Limitations

HCG can increase estrogen levels (via aromatization) and may cause testicular desensitization with chronic high-dose use. Some men also report mood changes or water retention.

Growth Hormone Peptides and Fertility

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) don't directly stimulate the HPG axis, but they play supporting roles in spermatogenesis.

IGF-1's Role

IGF-1 is a single-chain peptide composed of 70 amino acids. It's produced in the liver in response to GH, but it's also made locally in the testes. Both systemic and paracrine IGF-1 are involved in sperm development.

IGF-1 stimulates spermatogonial stem cell proliferation and differentiation, increases sperm motility, and correlates with total sperm count. It also appears to work synergistically with FSH — adding both IGF-1 and FSH to Sertoli cells in vitro produces greater proliferation than either alone.

In one case report, a man with severe oligoasthenoteratozoospermia (low count, poor motility, abnormal morphology) saw a 15.5-fold increase in sperm production after two months of IGF-1 treatment.

Animal studies have shown that local IGF-1 and GH treatment improved germ cell histology and spermatogenesis in prepubertal rats and mice. In high-fat diet-treated mice, IGF-1 promoted testicular sperm production by reducing germ cell apoptosis.

Growth Hormone-Releasing Peptides

Peptides like CJC-1295 (with or without ipamorelin) stimulate GH release, which in turn raises IGF-1. These peptides are sometimes included in fertility protocols, though the evidence is indirect.

The logic: higher GH and IGF-1 may improve metabolic health, reduce oxidative stress, and support the testicular microenvironment. But there are no large-scale human trials demonstrating that GH-releasing peptides directly improve sperm parameters.

Tesamorelin

Tesamorelin is a GH-releasing hormone analog. It's FDA-approved for reducing visceral fat in HIV patients, but some clinics explore it for metabolic optimization in fertility contexts. Again, the link to fertility is speculative rather than established.

BPC-157: Testicular Protection in Animals

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein in gastric juice. It has demonstrated tissue-protective and anti-inflammatory effects in animal models.

Preclinical Evidence

Rodent studies suggest that BPC-157 can protect against testicular damage induced by toxins and oxidative stress. Topical or systemic BPC-157 reduced tissue inflammation, accelerated wound healing, and offered protection from gonad-toxic agents.

If BPC-157 restores testicular blood flow (such as after varicocele or trauma) or reduces inflammatory damage, spermatogenesis could theoretically improve. But these are hypotheses, not proven mechanisms.

Human Data

There are virtually no human clinical trials evaluating BPC-157 for fertility outcomes. The peptide is not FDA-approved, and the FDA has actually raised safety concerns about BPC-157 sold by compounding pharmacies.

While anecdotal reports circulate in biohacking communities, the lack of rigorous clinical research means BPC-157's role in male fertility remains speculative.

Other Neuropeptides Under Investigation

Research has identified several neuropeptides that may influence male fertility, though clinical applications are even further off.

PACAP and VIP

Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are expressed in male reproductive tissues. A 2024 study found that seminal PACAP levels differentiated between subfertile and fertile men, with lower PACAP associated with low sperm count and motility.

These peptides appear to regulate steroidogenesis and penile erection, but therapeutic use is not yet established.

Seminal Peptides

The seminal fluid contains various peptides that modulate sperm motility, including neutral endopeptidase inhibitors. One example is opiorphin, which may enhance sperm function by inhibiting enzymes that would otherwise degrade motility-promoting peptides.

These are areas of active research but not yet actionable for clinical practice.

GLP-1 Receptor Agonists: A Metabolic Fertility Link

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide are used for weight loss and diabetes management. Recent research suggests they may have unexpected effects on male fertility.

A 2025 randomized controlled trial found that obese men with type 2 diabetes and hypogonadism experienced significant improvement in sperm morphology after 24 weeks of semaglutide 1 mg weekly (normal morphology increased from 2% to 4%, p = 0.012).

Preclinical studies indicate that GLP-1 receptor agonists enhance spermatogenesis, hormone profiles, and sperm function in obese or diabetic rodent models, likely through cAMP/PKA and PI3K/Akt pathways.

The mechanism appears to be metabolic: reducing obesity and insulin resistance improves the testicular environment, oxidative stress, and hormone signaling. This is an emerging area with limited but promising data.

Clinical Protocols: How Fertility Clinics Use Peptides

Fertility clinics generally don't start with peptides. The first-line approach for men with hypogonadism who want to preserve fertility is to avoid TRT entirely and use HCG with or without FSH.

When peptides are considered, protocols typically look like this:

Gonadorelin Protocols

Dose: 100-200 mcg subcutaneously, twice daily (to approximate pulsatile GnRH release)
Duration: Ongoing, as long as fertility preservation is desired
Monitoring: LH, FSH, testosterone levels every 4-6 weeks; semen analysis every 3-6 months
Goal: Maintain testicular function while on TRT or as an alternative to TRT

Kisspeptin Protocols

Dose: Varies widely; clinical trials have used 0.3-1.0 nmol/kg IV, but subcutaneous dosing protocols are less standardized
Duration: Experimental; not yet part of routine clinical practice
Monitoring: Reproductive hormones, semen analysis
Goal: Restore or maintain HPG axis function

HCG + FSH (Standard Fertility Treatment)

HCG: 250-500 IU subcutaneously, 2-3 times per week
FSH: Added if HCG alone doesn't restore spermatogenesis; typical dose 75-150 IU, 2-3 times per week
Duration: 9-18 months on average
Monitoring: Testosterone, LH, FSH, semen analysis
Goal: Restore intratesticular testosterone and spermatogenesis in men with hypogonadotropic hypogonadism or those recovering from TRT

Combination Protocols

Some clinics combine peptides — for example, low-dose HCG with growth hormone-releasing peptides — though evidence supporting these stacks is anecdotal rather than evidence-based.

Limitations of the Current Research

The peptide fertility field is early-stage. Here's what's missing:

Lack of large randomized controlled trials: Most peptide research relies on small studies, animal models, or case reports.

Inconsistent dosing protocols: Unlike pharmaceutical drugs with standardized regimens, peptide dosing varies widely between clinics and individuals.

Long-term safety data: Peptides like kisspeptin and gonadorelin have been used safely in short-term studies, but effects of years-long use are unknown.

Regulatory uncertainty: Many peptides are not FDA-approved for fertility indications. Compounding pharmacies have faced increasing scrutiny, particularly after FDA actions against unapproved peptides in 2024.

Individual variability: Response to peptides depends on baseline hormone levels, cause of infertility, age, and other factors. What works for one person may not work for another.

When to See a Specialist

If you're dealing with infertility or considering peptides for fertility preservation, start with a reproductive endocrinologist or urologist who specializes in male fertility — not a general TRT clinic or wellness center.

A fertility specialist will:

Order a semen analysis (the cornerstone of male fertility evaluation)
Check hormone levels (LH, FSH, testosterone, prolactin, estradiol)
Screen for underlying causes (varicocele, genetic factors, infections)
Discuss evidence-based treatments before experimental peptides

Peptide clinics can provide access to compounds like gonadorelin or kisspeptin, but they often lack the diagnostic rigor and fertility-specific expertise of a reproductive medicine practice.

If you're already on TRT and want to have children, talk to your doctor about transitioning to HCG or adding FSH rather than continuing exogenous testosterone.

The Bottom Line

Peptides offer a conceptually appealing alternative to TRT for men who want to support testosterone while preserving fertility. By working with the HPG axis rather than suppressing it, peptides like gonadorelin and kisspeptin aim to maintain the body's natural hormone production.

The science is promising but incomplete. Gonadorelin has a timing problem that limits its reliability. Kisspeptin shows potential in early trials but lacks large-scale validation. Growth hormone peptides may support fertility indirectly through metabolic and testicular microenvironment effects, but direct evidence is thin. BPC-157 remains speculative.

HCG, despite not being a peptide, is the most established option for men who need hormone support without shutting down spermatogenesis.

If fertility is a priority, avoid standard TRT. If you're already on it and want to conceive, expect a months-long recovery process — and even then, success isn't guaranteed. Peptides may help, but they're not a magic bullet.

Work with a specialist. Get baseline testing. Monitor your progress. And understand that male fertility treatment, whether peptide-based or conventional, requires patience, precision, and realistic expectations.

References

Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4424520/
Leslie SW, Soon-Sutton TL, Khan MA. Male Infertility. StatPearls. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK562258/
Luo Y, Chen Y, Zhou Y, et al. Global, regional and national burden of male infertility in 204 countries and territories between 1990 and 2019: an analysis of global burden of disease study. BMC Public Health. 2023;23:2227. https://link.springer.com/article/10.1186/s12889-023-16793-3
Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2(2):106-113. https://tau.amegroups.org/article/view/2249/html
Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility. World J Mens Health. 2019;37(1):45-54. https://pmc.ncbi.nlm.nih.gov/articles/PMC6305868/
Desai A, Yassin M, Cayetano A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic–androgenic steroids (AAS). Ther Adv Reprod Health. 2022;16:1-12. https://journals.sagepub.com/doi/10.1177/17562872221105017
Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. https://pmc.ncbi.nlm.nih.gov/articles/PMC3232613/
George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. https://pmc.ncbi.nlm.nih.gov/articles/PMC4507333/
Alshammari N, Albalawi A, Alshammari A, et al. Kisspeptins Regulating Fertility: Potential Future Therapeutic Approach in Infertility Treatment. J Clin Med. 2025;14(10):3284. https://www.mdpi.com/2077-0383/14/10/3284
Mahran A, Shahba A, Farag F, et al. Kisspeptin as a marker for male infertility: a comparative study of serum and seminal plasma kisspeptin between fertile and infertile men. J Assist Reprod Genet. 2025. https://link.springer.com/article/10.1007/s10815-025-03644-w
Liu X, Zhang R, Li Y, et al. Insulin-like growth factor-1 promotes the testicular sperm production by improving germ cell survival and proliferation in high-fat diet-treated male mice. Andrology. 2025;13(2):e13645. https://onlinelibrary.wiley.com/doi/10.1111/andr.13645
Mora Rodríguez JA, Porchia LM, Camargo F, López-Bayghen E. The use of insulin-like growth factor 1 improved the parameters of the seminogram in a patient with severe oligoasthenoteratozoospermia. SAGE Open Med Case Rep. 2019;7:1-4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6404043/
Cannarella R, Condorelli RA, Mongioì LM, La Vignera S, Calogero AE. Effects of the insulin-like growth factor system on testicular differentiation and function: a review of the literature. Andrology. 2018;6(1):3-9. https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12444
Hamza M, Ghonim I, Fakhreldin M. Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide in male fertility. Medicina (Kaunas). 2024;60(4):652. https://www.mdpi.com/1648-9144/60/4/652
Gregorič A, Blaha M, Čerňan M, et al. Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions. Urology. 2025. https://www.sciencedirect.com/science/article/abs/pii/S0090429525009124